NCT07254793Toboroz1. fázis
Prophylactic DLI-X for Leukemia Relapse After HCT
A Feasibility/Pilot First-in-human Study of Exercise-mobilized NK-enriched Donor Lymphocyte Infusions (DLI-X) to Prevent Leukemia Relapse After Allogeneic Hematopoietic Cell Transplantation
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. okt. 29.
Rövid összefoglaló (regiszter, angolul)
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. We hypothesize that pro-DLI-X will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).
- Állapot (regiszter)
- Toboroz
- Fázis (regiszter)
- 1. fázis
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 180 (tervezett)
- Első benyújtás
- 2025. nov. 19.
- Kezdés
- 2026. okt. 26.
- Elsődleges befejezés
- 2030. jún. 1.
- Fő szponzor
- University of Arizona
- Betegségek
- Akut limfoid leukémia (ALL), Akut mieloid leukémia (AML), Gyermekkori daganatok, Krónikus limfoid leukémia (CLL), Krónikus mieloid leukémia (CML), Mielodiszplasztikus szindróma (MDS)
- NCT-szám
- NCT07254793
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó · 1. fázis
- Tervezett résztvevők: 180
- 2026. okt. 26. és az elsődleges befejezés (2030. jún. 1.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
A regiszterben nem jelölt feltételek
- DLI Recipient Inclusion Criteria:
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 0-65 years
- Diagnosis of acute leukemia (lymphoid, myeloid or undifferentiated) myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) or non-Hodgkin's lymphoma (NHL)
- Undergoing myeloablative or reduced intensity matched sibling donor (MSD) HCT or haploidentical HCT
- Have a locally available healthy matched or haploidentical (≥5/10 HLA antigen matched) related donor between 12 and 50 years of age, consented and able to perform the exercise sessions. (see donor inclusion criteria)
- DLI Donor Inclusion Criteria:
- Provision of signed and dated informed consent form
- Must have already met transplant donor eligibility as a matched sibling donor, or HLA-haploidentical relative of the patient, including biological parents, siblings, or children, half-siblings, cousins or aunts and uncles
- Weight is greater than 30 kg
- Age 12 and 50 years
- Ability to undergo phlebotomy
- Be able complete the fitness evaluation to determine VO2max and peak cycling power. Following successful completion of the donor fitness evaluation, the patients willing to participate in the randomized trial will be enrolled
- Donor's recipient has met eligibility requirements and agreed to participate
- DLI Recipient Exclusion Criteria:
- Acute grade II-IV aGvHD or moderate/severe chronic GvHD at time of scheduled DLI.
- Requiring immunosuppression therapy for treatment of GvHD.
- Co-morbidities: AST/ALT greater than 5 x ULN; Bilirubin greater than 2 x ULN; Creatinine greater than 2 x ULN for age or creatinine clearance/GFR <40 ml/min/1.73m2; Pulmonary function: DLCO less than 40% of normal or O2 Sat less than 92%; Cardiac: left ventricular ejection fraction less than 35%; active infection; HIV positive; Karnofsky score (adults) less than 60% or Lansky score less than 50% (pediatrics)
- Uncontrolled or severe bacterial, fungal or viral infection.
- Positive serum or urine pregnancy test for girls post menarche or women of childbearing age.
- Severe psychiatric illness or mental deficiency making compliance to treatment unlikely and/or and/or would preclude informed consent according to IRB requirements for the study.
- Any reason, at the investigator's discretion, that the participation of the patient in this protocol would not be in patient's best interest, or where the patient would be unable to adhere to the study requirements.
- DLI Donor Exclusion Criteria:
- Unable to perform graded exercise test
- Cardiac or pulmonary disease/condition that would restrict exercise
- Positive anti-donor HLA antibody
- Pregnant or lactating
- Active infection
- Severe psychiatric illness or mental deficiency making compliance with donation unlikely and/or would preclude informed consent according to IRB requirements for the study.
Életkor a regiszterben: - – 65 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Egyesült Államok | Toboroz |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.